Targeted Drug Shrinks Tumors In Hard-To-Treat Cancer
RSS SUMMARY · AGGREGATED FROM FORBES
A targeted antibody‑drug conjugate shrinks tumors and slows progression in recurrent uterine cancer by ferrying potent chemotherapy directly into cancer cells.
A targeted antibody‑drug conjugate shrinks tumors and slows progression in recurrent uterine cancer by ferrying potent chemotherapy directly into cancer cells.
A targeted antibody‑drug conjugate shrinks tumors and slows progression in recurrent uterine cancer by ferrying potent chemotherapy directly into cancer cells.
Continue Reading
The full story continues on Forbes.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
FORBES
Tech
How AI Is Driving Wearable Tech As The Future Of Personal Computing
FORBES·57m ago·3 min read
Tech
This WALL-E Self-Driving Pod Wants To Replace The Airport Wheelchair (And Much More)
FORBES·1h ago·3 min read
Tech
‘The Chestnut Man’ Season 2 Ruined The Show With Its Controversial Death
FORBES·1h ago·3 min read
Tech
NYT ‘Pips’ Hints, Answers And Walkthrough For Thursday, June4
FORBES·2h ago·3 min read
Related
On this beat
Tech
Garmin says older runners are surprisingly doing the longest runs — see how you compare in the latest fascinating Connect data
TECHRADAR·51m ago·3 min read
Tech
Hey, remember that bonkers folding micro-LED TV? It’s back! And now it’s a Bugatti
TECHRADAR·51m ago·3 min read
Tech
How AI Is Driving Wearable Tech As The Future Of Personal Computing
FORBES·57m ago·3 min read
Tech
This WALL-E Self-Driving Pod Wants To Replace The Airport Wheelchair (And Much More)
FORBES·1h ago·3 min read